文献速递淋巴瘤白血病

阿可替尼单药治疗慢性淋巴细胞白血病(ACE-CL-001):开放标签、单臂、1-2期研究的里氏转化队列分析

Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study.
PubMed 文献 · Lancet Haematol · 2021-11-01

该开放标签、单臂、1-2期研究分析了25例里氏转化患者接受阿可替尼200 mg每日两次单药治疗的安全性和活性。总缓解率为40.0%(95% CI 21.1-61.3),中位无进展生存期为3.2个月(95% CI 1.8-4.0)。作者认为阿可替尼单药在此背景下应用有限,但有必要进一步评估其联合方案。

要点

  • 里氏转化患者接受阿可替尼单药治疗的总缓解率为40.0%(95% CI 21.1-61.3)。
  • 中位无进展生存期为3.2个月(95% CI 1.8-4.0),中位缓解持续时间为6.2个月(95% CI 0.3-14.8)。
  • 作者认为阿可替尼单药在此背景下应用有限,但有必要进一步评估其联合方案。

核心结论

  • 阿可替尼似乎总体耐受性良好,但该里氏转化队列的无进展生存期相对较差。
  • 基于这些发现,阿可替尼单药在此背景下的应用有限;然而,有必要进一步评估阿可替尼作为联合方案的一部分用于里氏转化患者。

研究设计与样本

  • 开放标签、单臂、1-2期研究,评估选择性、不可逆Bruton酪氨酸激酶抑制剂阿可替尼治疗慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的安全性和活性。
  • 里氏转化队列纳入25例年龄≥18岁、经活检证实的初治或经治弥漫大B细胞淋巴瘤(里氏转化)或幼淋巴细胞白血病转化、东部肿瘤协作组体能状态≤2的患者。
  • 患者来自四个国家的七个中心,接受口服阿可替尼200 mg每日两次单药治疗直至疾病进展或毒性。
  • 安全性和药代动力学为主要终点;次要终点为总缓解率、缓解持续时间和无进展生存期。
  • 安全性在所有治疗人群中评估,活性在所有治疗人群(无进展生存期)和疗效可评估人群(缓解率)中评估。

主要发现

  • 2014年9月2日至2016年4月25日纳入25例里氏转化患者;12例(48%)为男性,23例(92%)为白人。
  • 截至数据截止日(2021年3月1日),25例患者中2例(8%)仍在接受阿可替尼治疗;中位研究时间为2.6个月(IQR 1.8-8.4)。
  • 最常见的不良事件(所有级别)为腹泻(25例中12例[48%])、头痛(11例[44%])和贫血(8例[32%]);最常见的3-4级不良事件为中性粒细胞减少(25例中7例[28%])和贫血(5例[20%])。
  • 最常见的治疗中止原因为疾病进展(25例中17例[68%]);末次阿可替尼给药后30天内报告11例(44%)死亡,均未被认为与治疗相关。
  • 阿可替尼吸收和消除迅速,第1天和第8天暴露量相似;总缓解率为40.0%(95% CI 21.1-61.3),其中25例中2例(8%)完全缓解、8例(32%)部分缓解;中位缓解持续时间为6.2个月(95% CI 0.3-14.8);总体队列中位无进展生存期为3.2个月(95% CI 1.8-4.0)。

临床怎么用

  • 作者认为,基于这些发现,阿可替尼单药在此背景下的应用有限;然而,有必要进一步评估阿可替尼作为联合方案的一部分用于里氏转化患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with chronic lymphocytic leukaemia who progress to Richter transformation (diffuse large B-cell lymphoma morphology) have few therapeutic options. We analysed data from the Richter transformation cohort of a larger, ongoing, phase 1-2, single-arm study evaluating the safety and activity of the selective, irreversible Bruton's tyrosine kinase inhibitor acalabrutinib for the treatment of chronic lymphocytic leukaemia or small lymphocytic lymphoma. METHODS: For this open-label, single-arm, phase 1-2 study, patients aged 18 years or older with biopsy-proven treatment-naive or previously treated diffuse large B-cell lymphoma (Richter transformation) or prolymphocytic leukaemia transformation (Eastern Cooperative Oncology Group performance status ≤2) were assigned to receive oral acalabrutinib 200 mg twice daily as monotherapy until disease progression or toxicity. Patients were enrolled across seven centres from four countries. Safety and pharmacokinetics were assessed as primary endpoints; secondary endpoints were overall response rate, duration of response, and progression-free survival. Safety was assessed in the all-treated population (patients who received ≥1 dose), and activity was assessed in the all-treated population (for progression-free survival) and efficacy-evaluable population (for response rate; patients in the all-treated population with ≥1 response assessment after the first dose). This trial is registered with ClinicalTrials.gov (NCT02029443). FINDINGS: Between Sept 2, 2014, and April 25, 2016, 25 patients with Richter transformation were enrolled; 12 (48%) were male and 23 (92%) were White. As of data cutoff (March 1, 2021), two (8%) of 25 patients remained on acalabrutinib. The median time on study was 2·6 months (IQR 1·8-8·4). The most common adverse events (all grades) were diarrhoea (12 [48%] of 25 patients), headache (11 [44%]), and anaemia (eight [32%]). The most common grade 3-4 adverse events were neutropenia (seven [28%] of 25) and anaemia (five [20%]). The most common reason for treatment discontinuation was disease progression (17 [68%] of 25 patients). 11 (44%) deaths were reported within 30 days of the last acalabrutinib dose; none was considered treatment-related. Acalabrutinib was rapidly absorbed and eliminated, with similar day 1 and day 8 exposures. The overall response rate was 40·0% (95% CI 21·1-61·3), with two (8%) of 25 patients having a complete response and eight (32%) having a partial response; the median duration of response was 6·2 months (95% CI 0·3-14·8). Median progression-free survival in the overall cohort was 3·2 months (95% CI 1·8-4·0). INTERPRETATION: Acalabrutinib appears to be generally well tolerated, although progression-free survival was relatively poor in this cohort of patients with Richter transformation. On the basis of these findings, the use of acalabrutinib monotherapy in this setting is limited; however, further assessment of acalabrutinib as part of combination-based regimens for patients with Richter transformation is warranted. FUNDING: Acerta Pharma, a member of the AstraZeneca Group.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Eyre TA, Schuh A, Wierda WG, et al. Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. Lancet Haematol. 2021. PMID: 34735860. doi:10.1016/S2352-3026(21)00305-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。